Format

Send to:

Choose Destination
See comment in PubMed Commons below
Int Angiol. 2005 Sep;24(3):304-7.

Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab.

Author information

  • 1Department of Angiology, Ludwig-Maximilians-University of Munich, Munich, Germany. federico.tato@med.uni-muenchen.de

Abstract

Treatment of Takayasu's arteritis remains a demanding challenge to clinicians. In many patients the course of the disease is characterized by frequent relapses and disease progression under conventional treatment with glucocorticoids and cytotoxic drugs. We present the case of a young woman with severe cerebrovascular and aortic involvement, who experienced disease progression in spite of more than 2 years of treatment with high doses of prednisone, methotrexate and cyclophosphamide. In this patient, treatment with the human, monoclonal anti-tumor necrosis factor-alfa (TNFalfa)-antibody adalimumab achieved clinical remission and allowed tapering of prednisone within a few months. The present case, as well as previous reports on the use of infliximab in giant cell and Takayasu's arteries, suggests that TNFa-blockade may be a new, promising treatment for glucocorticoid-refractory large-vessel vasculitis.

PMID:
16158044
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk